Unlock stock picks and a broker-level newsfeed that powers Wall Street.
BSE - Delayed Quote INR

Aarti Drugs Limited (AARTIDRUGS.BO)

Compare
332.85
-15.90
(-4.56%)
At close: 3:59:04 PM GMT+5:30
Loading Chart for AARTIDRUGS.BO
  • Previous Close 348.75
  • Open 348.50
  • Bid 332.95 x --
  • Ask 334.15 x --
  • Day's Range 327.60 - 348.75
  • 52 Week Range 327.60 - 632.10
  • Volume 47,610
  • Avg. Volume 17,590
  • Market Cap (intraday) 30.379B
  • Beta (5Y Monthly) 0.70
  • PE Ratio (TTM) 20.00
  • EPS (TTM) 16.64
  • Earnings Date May 1, 2025 - May 5, 2025
  • Forward Dividend & Yield 1.00 (0.29%)
  • Ex-Dividend Date Feb 4, 2025
  • 1y Target Est 465.00

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, moxifloxacin, norfloxacin, ofloxacin, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, benzene sulphonic acid methyl ester, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for the antioxidant, antifungal, cardiovascular, and antidiabetic therapeutic areas. The company was incorporated in 1984 and is headquartered in Mumbai, India.

www.aartidrugs.co.in

1,064

Full Time Employees

March 31

Fiscal Year Ends

Recent News: AARTIDRUGS.BO

View More

Performance Overview: AARTIDRUGS.BO

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

AARTIDRUGS.BO
27.57%
S&P BSE SENSEX (^BSESN)
3.55%

1-Year Return

AARTIDRUGS.BO
31.53%
S&P BSE SENSEX (^BSESN)
1.53%

3-Year Return

AARTIDRUGS.BO
28.71%
S&P BSE SENSEX (^BSESN)
24.34%

5-Year Return

AARTIDRUGS.BO
149.63%
S&P BSE SENSEX (^BSESN)
173.15%

Compare To: AARTIDRUGS.BO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AARTIDRUGS.BO

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    31.83B

  • Enterprise Value

    37.44B

  • Trailing P/E

    20.97

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.38

  • Price/Book (mrq)

    2.49

  • Enterprise Value/Revenue

    1.62

  • Enterprise Value/EBITDA

    12.69

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.55%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    23.3B

  • Net Income Avi to Common (ttm)

    1.53B

  • Diluted EPS (ttm)

    16.64

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    295.6M

  • Total Debt/Equity (mrq)

    46.18%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: AARTIDRUGS.BO

View More

Company Insights: AARTIDRUGS.BO

Research Reports: AARTIDRUGS.BO

View More

People Also Watch